Aurolife Pharma LLC, et al.; Withdrawal of Approval of Five Abbreviated New Drug Applications

摘要

The Food and Drug Administration (FDA or Agency) is withdrawing approval of five abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.